-

Blue Matter Enhances Twine Platform Capabilities in Response to Growing Demand

SAN FRANCISCO--(BUSINESS WIRE)--Blue Matter today announced the expansion of its Twine™ data platform’s capabilities in response to accelerating demand from biopharma companies. Enhancements include thoughtful use of artificial intelligence (AI) for advanced analytics and narratives, expanded data source integrations, master data management, and broader deployment across oncology and specialty therapeutic areas.

Twine™ is Blue Matter's purpose-built customer intelligence platform for healthcare and life sciences companies. It transforms complex data from disparate sources including specialty pharmacy networks, hub services, claims databases, and other third party data sources into actionable insights that drive commercial strategy and operational excellence. With generative AI at its core, Twine helps companies more effectively acquire, master, validate, and analyze data from internal and third-party sources. Persona-specific outputs enable faster, more informed decision-making.

According to Deepak Gopinath, Partner at Blue Matter, "What started as a solution for managing complex oncology data has evolved into a comprehensive platform that's helping transform data into competitive advantage across multiple therapeutic areas. AI is thoughtfully woven into every aspect of the platform to support enhanced data integration, a natural language interface, and more. The response has been very encouraging."

Key enhancements include:

  • Advanced Analytics with AI: Incorporating proactive data narratives and reasoning capabilities to understand the “why” in addition to the “what”
  • Natural Language Interface: Enhanced natural language processing capabilities that allow users to query complex datasets using conversational interfaces in addition to standardized reports
  • Expanded Data Integrations: Pre-built connectors for more data sources and emerging digital health platforms
  • Enhanced Master Data Management: Sophisticated entity resolution and data stewardship workflows optimized for specialty pharmaceutical operations
  • Industry-Specific Accelerators: Pre-configured data models and KPIs tailored for a range of specialty therapeutic areas

Blue Matter continues to invest in Twine's technology roadmap, with even more improvements in the works. "We're proud of what we’ve built," said Prasanna Sridharan, Managing Partner of Blue Matter Insights. "But in the spirit of continuous improvement, we're constantly evolving it to meet our clients' changing needs. This expansion enables us to serve more companies while maintaining the specialized focus that makes Twine unique."

About Blue Matter

Blue Matter (www.bluematterconsulting.com) is a strategic consulting firm serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves pharmaceutical and biotech companies around the globe. The firm helps clients maximize value at the product, portfolio, and organization levels with a focus on corporate and product strategy in complex markets, as well as organizational effectiveness.

Contacts

For more information, contact:
Craig Dunkley
cdunkley@bluematterconsulting.com
(919) 539-0658

Blue Matter


Release Versions

Contacts

For more information, contact:
Craig Dunkley
cdunkley@bluematterconsulting.com
(919) 539-0658

More News From Blue Matter

Blue Matter Expands Capabilities in Healthcare Policy Support for Life Sciences Led by Partner, Milena Sullivan

NEW YORK--(BUSINESS WIRE)--Blue Matter today announced the launch of an expanded policy capability to support biopharma clients, led by Milena Sullivan, a Partner who joined the firm in December 2025. Milena Sullivan brings more than 20 years of experience in healthcare policy, advocacy, and market access, advising life science companies, trade associations, and provider organizations on policy issues shaping their business. Prior to joining Blue Matter, she spent almost a decade with Avalere H...

AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel

ROTTERDAM, Netherlands--(BUSINESS WIRE)--AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capab...

Blue Matter Launches People and Organization Practice to Help Biopharma Navigate Structural Shift

NEW YORK--(BUSINESS WIRE)--Blue Matter today announced the launch of its People and Organization Practice, a dedicated capability designed to help life science companies build organizations that can perform through complexity - from enterprise transformation and M&A integration to talent strategy, learning, and workforce redesign. The launch reflects a central conviction: the biopharma industry is not experiencing a cyclical downturn but a structural shift. With more than 42,700 jobs cut ac...
Back to Newsroom